51
The New Oral Anticoagulant s: Handle with Care Philip C. Comp, M.D., Ph.D. October 18, 2013

The New Oral Anticoagulants: Handle with Care

  • Upload
    rico

  • View
    54

  • Download
    0

Embed Size (px)

DESCRIPTION

The New Oral Anticoagulants: Handle with Care. Philip C. Comp, M.D., Ph.D. October 18, 2013. Speaker for dabigatran (Pradaxa®) and rivaroxaban (Xarelto®). Anticoagulant Quiz. Which commonly used anticoagulant does not require laboratory monitoring? Which anticoagulant has no antidote? - PowerPoint PPT Presentation

Citation preview

Page 1: The New Oral Anticoagulants: Handle with Care

The New Oral Anticoagulants:

Handle with CarePhilip C. Comp, M.D., Ph.D.

October 18, 2013

Page 2: The New Oral Anticoagulants: Handle with Care

Speaker for dabigatran (Pradaxa®) and rivaroxaban (Xarelto®)

Page 3: The New Oral Anticoagulants: Handle with Care

Anticoagulant Quiz• Which commonly used anticoagulant does

not require laboratory monitoring? • Which anticoagulant has no antidote?• The dose of which anticoagulant depends on

renal function?

(Enoxaparin, Lovenox®)

Page 4: The New Oral Anticoagulants: Handle with Care

Edoxaban

Page 5: The New Oral Anticoagulants: Handle with Care

The New Oral Anticoagulants

Dabigatran (Pradaxa®)Inhibits thrombinTwice a dayAtrial fibrillation

Apixaban (Eliquis®)Inhibits factor XaTwice a dayAtrial fibrillation

Rivaroxaban (Xarelto®)Inhibits factor XaOnce a dayAtrial fibrillation; DVT/PE treatment;Reduction in risk of DVT/PE (after 6 mn Tx);Hip/Knee prophylaxis;

Page 6: The New Oral Anticoagulants: Handle with Care

Canine Model of Blood Coagulation

Factor IX Factor X PROTHROMBIN

Page 7: The New Oral Anticoagulants: Handle with Care

Canine Model of Blood CoagulationEffect of Warfarin

Factor IXa Factor Xa THROMBIN

Page 8: The New Oral Anticoagulants: Handle with Care

Canine Model of Blood CoagulationOral Anti-Xa

Factor IXa Factor Xa THROMBIN

Page 9: The New Oral Anticoagulants: Handle with Care

Canine Model of Blood CoagulationOral Anti-thrombin

Factor IXa Factor Xa THROMBIN𝐝𝐚𝐛𝐢𝐠𝐚𝐭𝐫𝐚𝐧rivaroxaban

apixaban

Page 10: The New Oral Anticoagulants: Handle with Care

There is no free lunch

The effectiveness of an anticoagulant must be weighed against the risk of bleeding

Bleeding

Thrombosis

Page 11: The New Oral Anticoagulants: Handle with Care

Apixaban, Dabigatran and Rivaroxaban

• Oral• Short half-lives• Renal clearance• No INRs• No food interactions• Few drug interactions

Page 12: The New Oral Anticoagulants: Handle with Care

Prevention of Stroke-Apixaban

Granger et al. NEJM 3654: 981-92, 2011Number needed to treat/1.8 years: 167

Page 13: The New Oral Anticoagulants: Handle with Care

Atrial Fibrillation- Dabigatran

Connolly et al. NEJM 361, 2009

35% RRR

!

Number needed to treat/ 2 years: 88

Page 14: The New Oral Anticoagulants: Handle with Care

Atrial Fibrillation- Rivaroxaban

CPatel et al. NEJM 365: 883-91, 2011Number needed to treat/1.6 years: 135

Page 15: The New Oral Anticoagulants: Handle with Care

Atrial Fibrillation- Dabigatran

Modified from Connolly et al. NEJM 361, 2009

STRO

KENo Treatment Warfarin

Dabigatran

Number needed to treat NT 88 v. warfarin

No Tre

atm

ent

CHADS2 Scores

0-1 33%2 35%3-6 33%

ESTIMATE 5% risk/yearIn a non-treated group

Page 16: The New Oral Anticoagulants: Handle with Care

Percentage of AF patients with stroke per year

No treatment 5.0%Warfarin 1.6%Dabigatran 1.0%

~

Modified from Connolly et al. NEJM 361, 2009

3.4%

0.6%68% of strokes gone; 32 occur

80% of strokes gone; 20 occur

100 strokes occur

Page 17: The New Oral Anticoagulants: Handle with Care

STROKE = Ischemic Stroke and Hemorrhagic Stroke*

*Subdural hematomas, epidural hematomas, subarachnoid hematomas and intracerebral hemorrhage

Page 18: The New Oral Anticoagulants: Handle with Care

Stroke rates (percent/year)

All Stroke Hemorrhagic Stroke

Time INR in 2-3 range

Dabigatran/ Warfarin

1.44/1.57 0.10/0.38 64

Rivaroxaban/Warfarin(as treated)

2.61/3.12 0.5/0.7 55

Apixaban/ Warfarin

1.19/1.51 0.24/0.47 62

Page 19: The New Oral Anticoagulants: Handle with Care

Bleeding and death rates (percent/year)Major Bleeding

Death

Dabigatran/ Warfarin

3.11/3.36 3.64 /4.13

Rivaroxaban/Warfarin(as treated)

3.60/3.40 1.90/2.20

Apixaban/ Warfarin

2.13/3.09 3.52/3.94

Page 20: The New Oral Anticoagulants: Handle with Care

Bleeding Event Rate (%/year)Intracranial Gastrointestinal

Apixaban 0.33 0.76Warfarin 0.80 0.86

Dabigatran 0.30 1.51Warfarin 0.74 1.02

Rivaroxaban 0.77 3.15Warfarin 1.18 2.16

N Engl J Med 2011;365:981-92N Engl J Med 2009;361:1139-51.N Engl J Med 2011;365:883-91.

Page 21: The New Oral Anticoagulants: Handle with Care

NNT with dabigatran for 1 year to prevent one adverse event compared to warfarin

NNT

Stroke or systemic embolus

172

Intracranial bleeding 227

Major bleeding 154

Life-threatening bleeding

286

Nature Reviews Cardiology 7, 10-11 (January 2010)

Page 22: The New Oral Anticoagulants: Handle with Care

Can atrial fibrillation studies be directly compared?

Mean Age and CHADS2 Score

Apixaban 70y 2.1 ± 1.1

Rivaroxaban 73y 3.5 ± 0.94

Dabigatran 72y 2.1 ± 1.1

Direct comparison of strokes and bleeding between studies is difficult.

CHF 1Hypertension 1Age > 75 1Diabetes 1Prior stroke 2

Page 23: The New Oral Anticoagulants: Handle with Care

New oral agents in atrial fibrillation

Apixaban superior to warfarinRivaroxaban not inferior to warfarinDabigatran superior to warfarin

Davis, N Engl J Med 2012;366:1914-22.

Page 24: The New Oral Anticoagulants: Handle with Care

No food interactions

Compare to WARFARIN AND FOOD

Page 25: The New Oral Anticoagulants: Handle with Care

Dietitians

Page 26: The New Oral Anticoagulants: Handle with Care

CHLOROPHOBIA (fear of the color green)

Page 27: The New Oral Anticoagulants: Handle with Care

Green Tea

Page 28: The New Oral Anticoagulants: Handle with Care

Green Tea333 liters of green tea contain 1 mg vitamin K

Page 29: The New Oral Anticoagulants: Handle with Care

Iceberg Lettuce

Page 30: The New Oral Anticoagulants: Handle with Care

New anticoagulants have short half- lives (9-17 hours)

Compliance

Page 31: The New Oral Anticoagulants: Handle with Care

Forgetfulness 30%Other priorities 16%Decision to omit doses 11%Lack of information 9% Osterberg l et al. NEJM 353: 487-97 2005

Page 32: The New Oral Anticoagulants: Handle with Care

1,800,000 patients prescribed a statin:

Patients filled prescriptions for a mean of 11.4 medications/3 month

10% of patients filled prescriptions for 23 or more medications.

10% had prescriptions written by 4 or more prescribers.

Choudhry NK The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications. Archives of Internal Medicine 171:814-822, 2011

Page 33: The New Oral Anticoagulants: Handle with Care

Retrospective Study of Medication Prescription in Oklahoma City, n=3

• 64 year old man: 14 medications daily; 31 pills• 61 year old woman: 15 medications; 39 pills• 90 year old man: 15 medications; 27 pills

Page 34: The New Oral Anticoagulants: Handle with Care

Drugs don’t work in patients who don’t take them C. Everett Koop, M.D.

1916-2013

Page 35: The New Oral Anticoagulants: Handle with Care

Typical Clinical Trial Patient

Page 36: The New Oral Anticoagulants: Handle with Care

Who is the ideal patient?

• Does not like INRs• Reliable• Well insured

Page 37: The New Oral Anticoagulants: Handle with Care

Who will have a bleed?

• Frail (<60 kg)• Reduced creatinine clearance• Over 80 years of age

Harper. Bleeding Risk with Dabigatran in the Frail ElderlyN Engl J Med 2012; 366:864-866

Page 38: The New Oral Anticoagulants: Handle with Care

Proper prescriber behavior

• At each visit – Are your taking drug X?• At every visit – Why are you taking drug X?• At each visit – Are you taking X every day?

Page 39: The New Oral Anticoagulants: Handle with Care

KIDNEY FUNCTION IS IMPORTANT!CHECK THE CREATININE CLEARANCE

Page 40: The New Oral Anticoagulants: Handle with Care

What is the effect of no more INRs?

No more anticoagulation clinics and fewer office visits.Will that reduce compliance?

BOUNCING BEN in a BAD candidate!

00.5

11.5

22.5

33.5

44.5

INR

Page 41: The New Oral Anticoagulants: Handle with Care

Who to switch from warfarin

• Not a cure for the bouncing INR• Stroke risk: Least benefit to well controlled

warfarin patients• Fewer potential drug interactions in

polypharmacy patients?

Page 42: The New Oral Anticoagulants: Handle with Care

Warfarin > new anticoagulant

Patients angst: Miss INRsMiss food restrictions

Page 43: The New Oral Anticoagulants: Handle with Care

If bleeding occurs

Little data availablea. Factor VIIab. Factor VIII Inhibitor Bypassing Activity (FEIBA)c. Hydration

Fresh frozen plasma and Vitamin K are not the way to go!

Page 44: The New Oral Anticoagulants: Handle with Care

Everyone is developing an antidote

Oral anticoagulant inhibits factor Xa

Xa

Inhibitor

Page 45: The New Oral Anticoagulants: Handle with Care

Everyone is developing an antidote

A recombinant antidote (DU-176b)

Xa

Page 46: The New Oral Anticoagulants: Handle with Care

Surgery while on medication

Dabigatran (100% renal)Rivaroxaban (65% renal clearance)Apixaban (25% renal clearance)

When to stop the medication preoperatively depends on the medication and renal function.

Look it up!

Page 47: The New Oral Anticoagulants: Handle with Care

What is the cost per day*

Dabigatran = $9.50Rivaroxaban= $9.46Apixaban = $9.40

*Sam's Club, Northwest Highway, OKC 10/10/13

Page 48: The New Oral Anticoagulants: Handle with Care

Advising patients

• Explain they are taking lots of medications – stroke preventers critical • Avoid friendly little black dogs and

get someone else to clean the gutters!

Page 49: The New Oral Anticoagulants: Handle with Care
Page 50: The New Oral Anticoagulants: Handle with Care

Summary of New Anticoagulants

• Marginally better than warfarin for atrial fibrillation

• No food interactions; few drug interactions• No need for INRs• Short-half life – take regularly• Check creatinine clearance yearly

Page 51: The New Oral Anticoagulants: Handle with Care